Clinical review report: Cysteamine 3.8 mg/mL ophthalmic solution (Cystadrops) (Recordati Rare Diseases Canada Inc.)
The objective of this review is to perform a systematic review of the beneficial and harmful effects of cysteamine 3.8 mg/mL (CH 0.55% by weight) ophthalmic solution (Cystadrops) for the treatment of corneal cystine crystals deposits in adults and children from two years of age with cystinosis
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa
Canadian Agency for Drugs and Technologies in Health
July 2019, 2019
|
Edition: | Version: final (with redactions) |
Series: | CADTH common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of this review is to perform a systematic review of the beneficial and harmful effects of cysteamine 3.8 mg/mL (CH 0.55% by weight) ophthalmic solution (Cystadrops) for the treatment of corneal cystine crystals deposits in adults and children from two years of age with cystinosis |
---|---|
Physical Description: | 1 PDF file (84 pages) illustration |